New Delhi, PTI. According to the first real-world assessment of India’s indigenous corona vaccine published in The Lancet Infectious Disease journal, both doses of Covaccine are up to 50 percent effective against COVID-19. Results from an interim study recently published in The Lancet showed that two doses of Covaxin, also known as BBV152, had 77.8 percent efficacy against the disease and showed no risk.
The latest study assessed 2,714 hospital workers at the All India Institute of Medical Sciences (AIIMS) in Delhi from April 15 to May 15 who had symptoms and underwent RT-PCR test to detect COVID-19. The researchers noted that the delta variant was a cause of major concern in India during the study period, accounting for nearly 80 per cent of all confirmed COVID-19 cases.
Covaccine, developed by Hyderabad-based Bharat Biotech in collaboration with National Institute of Virology, Indian Council of Medical Research (NIV-ICMR), Pune, is administered after 28 days of receiving one dose.
In January this year, Covaxin was approved for emergency use in India for people aged 18 years and above. At the same time, the World Health Organization (WHO) also recognized Covaxin for the Emergency Use List (EUL) earlier this month.
Manish Soneja, Additional Professor of Medicine, AIIMS, New Delhi, said, “Our study provides a complete picture of how BBV152 (Covaxin) works in the region and is considered in the context of the growth situation of COVID-19 in India. which is associated with the potential immunogenicity of the delta variant. He further said that our findings provide evidence that the rapid vaccine rollout program remains the most promising path to epidemic control, while public health policies should include additional protective measures such as mask-wearing and social distancing.
The COVID-19 Vaccination Center at AIIMS New Delhi exclusively offered Covaxin to all its 23,000 employees from January 16 this year. Researchers have evaluated the vaccine’s effectiveness against symptomatic and RT-PCR confirmed SARS-CoV-2 infection. Of the 2,714 employees in the study, 1,617 people tested positive for SARS-CoV-2 and 1,097 tested negative.